Göran Albert Ando

deCODE genetics, Inc. is a bio-pharmaceutical company. It developing and marketing products to improve the treatment, diagnosis and prevention of common diseases. deCODE applies its capabilities in chemistry and structural biology to the development of drugs in major therapeutic areas, and applies its discoveries in human genetics to bring to market DNA-based reference laboratory tests and consumer genome analysis services to assess individual risk of common diseases. The company was founded by Kari Stefansson and Jeffrey Gulcher in August 1996 and is headquartered in Reykjavík, Iceland.

Celltech Group Plc was one of the leading European biotechnology company which is engaged in discovery and development of innovative drugs. The company was located in Slough, United Kingdom.

Inion Oy is a medical devices company focused on the development and commercialization of innovative biodegradable and bioactive implants for applications in Spine and Specialty Orthopedics applications. By targeting key strategic markets in the USA and select territories in the rest of the world, Inion has built a product portfolio sold through a dedicated network of specialist distributors. Inion's products include biodegradable plates, screws, pins and membranes, which are used to enhance the healing of bone or soft tissue injuries, such as those caused by trauma or by reconstructive surgery. Inion's core expertise is in the design and manufacture of implants from its proprietary Inion Optima™ family of biomaterials, which enables the Company to develop medical implants with properties tailored for specific surgical applications, in terms of strength, flexibility and rate of degradation. Incorporated in 2000, Inion has offices in the UK and USA, and its head office, R&D and manufacturing facilities are in Tampere, Finland.

The International Centre for Missing & Exploited Children is an organization that focuses on finding missing children and protecting children from exploitation worldwide. The non-profit company is based in Alexandria, VA and the CEO of the company is Paul Shapiro. The company's work involves powering the search for missing children and implementing measures to safeguard children from harm.

SWMF Life Science Venture Fund LP invests in life science and medical device companies located in Southwest Michigan. It provides financing for start-up and early stage capital requirements.

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its portfolio includes pipeline, autoimmune, gene therapy, and biologic therapy. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian on December 10, 2007 and is headquartered in Watertown, MA.

Bristol-Myers Squibb Pharma Research Labs LLC researches and develops drugs and related pharmaceutical products. The company is headquartered in San Diego, CA

EDB Investments Pte Ltd (EDB Investments) is a Venture Capital firm founded in 1991. The firm is headquartered in Singapore.

Pharmacia Corp. developed, manufactured and marketed pharmaceutical products. Prescription pharmaceuticals included general therapeutics, ophthalmology and hospital products including oncology and diversified therapeutics. It also operated in consumer health care, animal health, diagnostics and contract manufacturing and bulk pharmaceutical chemicals. The customers of the group were pharmacies, hospitals, chain warehouses, governments, physicians, wholesalers and other distributors. It was headquartered in Peapack, NJ.

Novexel SA researches and develops anti-infective drugs for the treatment of bacterial and fungal infections. The firm focuses on discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance. The company was founded in December 2004 and is headquartered in Romainville, France.

Trigen Holdings AG develops drugs focusing on thrombosis and vascular dysfunction. Its product pipeline includes clinical stage candidates, TGN 255, TGN 167 and PR-15. The company has offices in London. Trigen Holdings was founded in 2005 and is headquartered in Martinsried, Germany.

Chroma Therapeutics Ltd. engages in the discovery and development of therapies for the treatment of cancer and inflammation. It focuses on the discovery and development of novel small molecule drugs based upon chromatin biology and novel cell accumulation approaches. The firm uses chromatin biology, drug accumulation approaches to discover and develop cancer, inflammation treatments and small molecule drugs. The company was founded by David Allis, Alan Hornsby Davidson, Alan Hastings Drummond, Anthony Kouzarides and Paul Workman in September 2001 and is headquartered in Abingdon, the United Kingdom.

Founded in 1935, Glaxo Group Ltd. is a subsidiary of GSK Plc. The private company is based in Middlesex, UK. At GSK, we unite science, technology and talent to get ahead of disease together.

CBio Ltd. focuses on developing new generation products for the treatment of autoimmune and inflammatory diseases. It develops and commercializes treatments for autoimmune diseases. The company focuses and develops technologies on commercializing its proprietary drug, XToll for autoimmune and inflammatory diseases. It develops technologies for the treatment of autoimmune and inflammatory diseases. The company also engages in the business of research, product development and clinical trials of the therapeutic drug XToll and development of variants to the company's Cpn10 technology. CBio was founded by Steve P. Jones on October 11, 2000 and is headquartered at Brisbane, Australia.

Archimedes Pharma UK Ltd. involves in marketing niche pharmaceutical products. The company is headquartered in London, the United Kingdom.

S*BIO is a privately-held biotech company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer with leading programs around histone deacetylases (HDAC) and kinases. S*BIO's lead candidate, SB939, entered the clinic in 2007. SB1518, S*BIO's potent and orally-active JAK2 inhibitor, entered the clinic in 2008 and has received orphan drug designation from the U.S. FDA. S*BIO has entered into a development collaboration, and option & license agreement with Onyx Pharmaceuticals, Inc. to develop and commercialize SB1518 and its other novel JAK2 inhibitor, SB1578. S*BIO's SB1317, a novel multikinase inhibitor, is in pre-clinical development and under a worldwide exclusive license with Tragara Pharmaceuticals, Inc. for its development and commercialization. In line with its vision to be a leading fully-integrated oncology-focused biotech company in Asia Pacific, S*BIO has established a state-of-the-art R&D infrastructure, complemented by a strong clinical development team. S*BIO has strong links with a network of medical oncologists in Asia Pacific and its investors include EDB Investments' biomedical sciences subsidiary Bio*One Capital, Aravis Ventures, Novartis Bioventures and other international funds. In 2009, S*BIO received the BioSpectrum Editor's Choice, Emerging BioScience Company of Singapore Award.

Symphogen A/S provides antibody therapeutics for the treatment of cancers. It offers oncology products and creates selected antibody mixtures that address multiple oncology targets in a single drug product. The firm’s pipeline is fueled by its technology suite capable of identifying, selecting, manufacturing, and characterizing optimal antibody mixtures. The company was founded by Kirsten Aarup Drejer, Thomas Feldthus, Eigil Bjerl Nielsen, Anker Gunvald Lundemose, Kim Arthur Hueg, and John Soerensen Haurum in 2000 and is headquartered in Ballerup, Denmark.

Albea Pharmaceuticals AG specializes in the development and marketing of pharmaceutical products. The company was founded by Werner Tschollar and is headquartered in Zug, Switzerland.

The American College of Rheumatology is an organization for physicians and health professionals. The non-profit company is based in Atlanta, GA. The company was founded by Göran Albert Torstensson Ando.

Jazz Pharmaceuticals UK Ltd. is pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, oncology supportive care and critical care products. The company was founded in 2006 and is headquartered in Oxford, United Kingdom.

Novo Nordisk Ltd. engages in the sale and marketing of pharmaceutical products for the treatment of chronic conditions in the United Kingdom. It offers medicines for the treatment of diabetes, and hemophilia and bleeding disorders, as well as for growth hormone therapy and hormone replacement therapy. The company is headquartered in Crawley, the United Kingdom.

Tessa Therapeutics Pte Ltd. engages in the development and commercialization of cancer immunotherapies. The firm has recruitment sites in Singapore, Malaysia, Taiwan, Thailand and the United States. The company was founded by Malcolm Brenner and Andrew Khoo and is headquartered in Singapore.

EUSA Pharma (UK) Ltd. supplies medicines and medical devices. It offers Caphosol, Xenazine, Collatamp, Custodiol, and Fomepizole. The company was founded in March 2015 and is headquartered in Hemel Hempstead, the United Kingdom.

Nouscom AG engages in the development of genetic neoantigen vaccines and oncolytic viruses for prevention and treatment of cancer. Its product pipeline include Nous-209, Nous-PEV, and Nous-THV-001. The company was founded by Alfredo Nicosia, Antonella Folgori, Riccardo Cortese, Stefano Colloca, Cinzia Traboni, Elisa Scarselli, and Gabriella Campadelli in 2007 and is headquartered in Basel, Switzerland.

Novo Holdings A/S (Investment Company) (Novo Holdings-IC) is the investment portfolio division of Novo Holdings A/S, a holding company headquartered in Hellerup, Denmark. They are ultimately owned by Novo Nordisk Fonden (Novo Nordisk Foundation). Founded in 1999, Novo Holdings-IC manages a broad portfolio of the Foundation’s financial assets.